BIIB News 343.36 08/28/2014 04:44:22 Biogen Idec Inc (BIIB)

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Biogen Idec Inc (BIIB) 343.36 $BIIB

After Recent Surge, Are Biotech ETFs Back on Track? - ETF News And Commentary
Zacks Equity Research - ZACKS - Wed Aug 27, 7:00AM CDT
Recent trends have been very favorable for the biotech sector, but can this run continue?

Biogen names Dr Donald R. Johns VP of its amyotrophic lateral sclerosis (ALS) Innovation Hub (ALS iHub)
M2 - Wed Aug 27, 5:48AM CDT
Medicine company Biogen (NasdaqGS:BIIB) disclosed on Tuesday that it has appointed Dr Donald R. Johns, MD as vice president of its amyotrophic lateral sclerosis (ALS) Innovation Hub (ALS iHub), a new, cohesive unit dedicated to accelerating the discovery and development of novel therapies for ALS.

Celgene, Gilead Lead Big Biotech Stock Movers
at Investor's Business Daily - Tue Aug 26, 4:55PM CDT
Big-cap biotechs moved in strong volume on the stock market today as Deutsche Bank added several to its short-term buy list, after Citi reported back from visits with medical experts. Celgene (CELG) hit a new high above 95 after Deutsche Bank analyst...

Biogen Idec in Panel at the Citi 9th Annual Biotech Conference
Business Wire - Tue Aug 26, 3:01PM CDT
Biogen Idec Inc. (NASDAQ: BIIB) announced today that it will participate in a panel at the Citi 9th Annual Biotech Conference. The webcast will be live on Thursday, September 4, 2014 at 10:00a.m. ET. To access the live webcast, please visit Biogen Idec's Investors section at www.biogenidec.com. An archived version of the webcast will be available for 14 days following the presentation.

Economic Data Fuel Another All-Time High For S&P 500
at Investor's Business Daily - Tue Aug 26, 2:36PM CDT
A big jump in durable goods orders and a strong reading on consumer confidence from the Conference Board fueled modest gains for the stock market Tuesday. The Dow Jones industrial average led the way, rising 0.3%. Exxon Mobil (XOM), UnitedHealth...

Donald Johns Joins Biogen Idec to Lead ALS Innovation Hub
Business Wire - Tue Aug 26, 7:00AM CDT
Biogen Idec (NASDAQ: BIIB) today announced that Donald R. Johns, M.D., has joined the company as vice president, leading Biogen Idec's amyotrophic lateral sclerosis (ALS) Innovation Hub (ALS iHub). The ALS iHub is a new, cohesive unit dedicated to accelerating the discovery and development of novel therapies for ALS by integrating research with clinical development. Dr. Johns reports directly to Alfred Sandrock, M.D., Ph.D., group senior vice president and chief medical officer.

Health Canada Approves Eloctate(TM), the First Therapy to Extend the Interval Between Prophylactic Infusions in Hemophilia A
CNW Group - Tue Aug 26, 7:00AM CDT
- Only Hemophilia A Therapy to Provide Bleeding Protection with Prophylactic Regimens of Either Every Three to Five Days or Once-Weekly Infusions -

Biogen, Celgene In Buy Range; LinkedIn Coming Back
at Investor's Business Daily - Mon Aug 25, 5:43PM CDT
Biotech stocks are well represented in this week's Big Cap 20, while LinkedIn (LNKD) and Facebook (FB) are pacing a rebound in Internet stocks. The Medical-Biomedical/Biotech industry has erased slightly more than half its losses since falling...

Stocks Hold Decent Gains; InterMune Deal Sparks Biotechs
at Investor's Business Daily - Mon Aug 25, 1:54PM CDT
Major averages held on to decent gains with a little over one hour remaining in Monday's session. After topping the 2000 level, the S&P 500 rallied 0.5%; the Dow Jones industrial average also gained 0.5% while the Nasdaq tacked on 0.3%. Nasdaq volume...

Majority Of IBD 50 Firms Strong On Sponsorship
at Investor's Business Daily - Fri Aug 22, 5:37PM CDT
Earnings growth fuels a stock's price performance, but that's not the only ingredient for a stock's success. Rising mutual fund sponsorship also helps. Stocks with solid sponsorship aren't hard to find every week in the IBD 50, but sponsorship runs...

Data on Celgene's Revlimid Published in Oncology Journal - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Aug 22, 4:35PM CDT
Encouraging data was published on Celgen's (CELG) Revlimid in DLBCL.

Biogen Idec appoints Adriana (Andi) Karaboutis as EVP of its Technology and Business Solutions
M2 - Fri Aug 22, 5:25AM CDT
Medicine company Biogen Idec (NasdaqGS:BIIB) disclosed on Thursday the election of Adriana (Andi) Karaboutis as executive vice president of its Technology and Business Solutions.

Watch for Biogen Idec to Potentially Rebound After Falling 1.15% Yesterday
Comtex SmarTrend(R) - Thu Aug 21, 3:53PM CDT
Biogen Idec (NASDAQ:BIIB) traded in a range yesterday that spanned from a low of $337.19 to a high of $344.42. Yesterday, the shares fell 1.1%, which took the trading range below the 3-day low of $340.67 on volume of 663,000 shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.

Biogen Idec Names Adriana Karaboutis EVP, Technology and Business Solutions
Business Wire - Thu Aug 21, 6:00AM CDT
Biogen Idec (NASDAQ: BIIB) today announced the appointment of Adriana (Andi) Karaboutis as executive vice president, Technology and Business Solutions, effective September 24, 2014. She will report directly to the company's chief executive officer, George Scangos, Ph.D., and will be a member of the Biogen Idec management team.

What Investors Gain from Large, Mid & Small-Cap Growth Funds - Mutual Fund Commentary
Zacks Equity Research - Zacks Investment Research - Wed Aug 20, 2:02PM CDT
For investors looking to invest in growth funds, we will suggest here the top growth funds from each market capitalization. These funds carry a Zacks Mutual Fund Rank #1 (Strong Buy) as we expect the funds to outperform its peers in the future

Biotech Stock Roundup: Achillion Scores in Mid-Stage Study, Gilead's Sovaldi Remains in Focus - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Aug 20, 10:08AM CDT
Last week, hepatitis C virus treatments remained in focus with Achillion and Gilead providing updates on ACH-3102 and Sovaldi, respectively.

US Orphan Drug Clinical Pipeline Insight 2014 - New Report on the $49 Billion Industry
M2 - Wed Aug 20, 8:25AM CDT
Research and Markets (http://www.researchandmarkets.com/research/q26z36/us_orphan_drug) has announced the addition of the "US Orphan Drug Clinical Pipeline Insight 2014" report to their offering. In 2013, the US market for orphan drugs was estimated worth US$ 49 Billion. With factors like government support, high profitability and many more, this market is expected to surpass US$ 60 Billion by 2018. The orphan drugs enjoy significant competitive advantages owing to the market exclusivity period after the drug has been authorized. Through this clause, the manufacturer of orphan drugs is given a monopoly status in the market because according to the law, no other company is allowed to market the orphan drugs during the exclusivity period. Additionally, this monopolistic power is further strengthened with the fact that no other alternative health technology exists for many orphan drugs. In US, the research & development of orphan drugs is facilitated by public programs, government regulations, and policies. The major incentives for research & development of orphan drug include grants, research support, fee waivers, tax incentives, and orphan drug market exclusivity. In a highly specialized market like that of orphan drugs, though the impact of market exclusivity in the US has been positive yet relatively modest, a special platform for continued orphan drug development has been laid down by the economic incentives and public support mechanisms. US Orphan Drug Pipeline Insight 2014 - Report Highlight: - US Orphan Drug Market Insight & Orphan Drug Designation Criteria - Reimbursement Policy & FDA Regulatory Framework - US Orphan Drug Pipeline by Phase, Indication & Company - Marketed Orphan Drug Clinical Insight - US Orphan Drug Clinical Pipeline: 570 Drugs - Marketed Orphan Drugs in US: 203 Drugs - Majority Orphan Drugs in PHASE-II Development: 207 Drugs Key Topics Covered: 1. Introduction to US Orphan Market - Market Overview - Clinical Pipeline Overview 2. US Orphan Drug Regulatory Framework - Criteria for Orphan Drug Designation - Reimbursement Policy for Orphan Drugs - FDA Regulation 3. US Orphan Drug Clinical Pipeline by Phase, Indication & Company - Unknown - Research - Preclinical - Clinical - Phase-I - Phase-I/II - Phase-II - Phase-II/III - Phase-III - Preregistration - Registered 4. Marketed Orphan Drugs Clinical Insight by Indication & Company 5. Suspended & Discontinued Orphan Drugs in Clinical Pipeline by Phase, Indication & Company - No development reported - Discontinued - Market Withdrawal - Suspended 6. Competitive Landscape - Alexion - Biogen Idec - Bristol Myers Squibb - Celgene - Eli Lilly - Glaxosmithkline - Merck - Novartis Pharmaceuticals - Pfizer - Roche - Rare Disease Therapeutics - Sanofi For more information visit http://www.researchandmarkets.com/research/q2...rphan_drug

Drug Approvals, Clinical Trial Result, and Philanthropic Activity - Research Reports on Johnson & Johnson, Biogen, Amgen, Medtronic and Merck
PR Newswire - Wed Aug 20, 8:20AM CDT
Today, Analysts Review released its research reports regarding Johnson & Johnson (NYSE: JNJ), Biogen Idec Inc. (NASDAQ: BIIB), Amgen, Inc. (NASDAQ: AMGN), Medtronic, Inc. (NYSE: MDT) and Merck (NYSE: MRK). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/5855-100free.
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Kinross Gold Fraud Lawsuit: What Shareholders Need to Know

Updated Category News Views 64

Kinross Gold's Legal Quagmire There's a fresh storm brewing for Kinross Gold Corporation (NYSE: KGC), and it ain't the kind investors enjoy riding. You see, the company is up to its neck in a class action lawsuit, courtesy of Schall, Brown & Schwartz LLP—a big-name shareholder rights litigation outfit. The gripe? Alleged securities fraud, violating §§10(b) and 20(a)...

Continue Reading
Animal Parasite Market Growth Has a Resistance Catch

Updated Category News Views 41

Flea collars and cattle worms do not sound glamorous, yet this is exactly where durable animal-health revenue gets built. Wissen Research puts the global animal parasiticides market at $13.6 billion in 2026 and projects $18.6 billion by 2031, a 6.5% compound annual growth rate. That is respectable, not moonshot stuff, and frankly that is part of the appeal. Pet owners...

Continue Reading
Stand Out For Good Makes a Bold Michigan Avenue Bet

Updated Category News Views 51

A six-floor retail commitment lands with a thud Stand Out For Good is taking on roughly 51,079 square feet at 669 North Michigan Avenue, and nobody should mistake that for a casual expansion. Six levels on Chicago's Magnificent Mile is a proper declaration of intent, especially in a retail district that has endured plenty of empty-window handwringing and big-brand churn....

Continue Reading
Stand Takes Colorado Bet on Wildfire-Smart Coverage

Updated Category News Views 21

Colorado’s insurance mess has finally attracted a company willing to price the driveway, the vents, and the tree line instead of shrugging at an entire ZIP code. Stand has launched homeowners coverage across the state, including mountain communities where wildfire exposure has made insurance both costly and scarce. This is not a small problem dressed up with a shiny...

Continue Reading
Vertiv's 800 VDC Push Gives AI Builders More Choices

Updated Category News Views 192

Electricity is becoming the awkward roommate inside every serious AI buildout, and Vertiv is trying to move it out of the rack before it eats the whole house. The company has expanded its 800 VDC offering beyond the PowerDirect 5000 rack product introduced in May 2026, laying out systems for the rack, the AI compute pod, and the full data hall. For investors following...

Continue Reading
Lennar Faces Legal Heat Over Alleged Misleading Statements

Updated Category News Views 152

Rumbling Legal Drama with Lennar Corporation Every trader knows the uneasy feeling when a stock you're eyeing takes a surprising nosedive on some legal muck coming out of the woodwork. Well, it's Lennar Corporation's turn in the spotlight for all the wrong reasons. They're getting slapped with a class action lawsuit by investors claiming the company pulled a fast one...

Continue Reading
OFRM Faces Legal Heat Over Toddler Snack Recall

Updated Category News Views 200

OFRM Under the Microscope: Who Saw This Coming? Smack dab in the middle of navigating everyday market volatility, here's Once Upon A Farm (NYSE: OFRM) taking the spotlight—but for all the wrong reasons. The company got slapped with a stark FDA warning. Their Tractor Wheels toddler snacks allegedly pose a choking risk— think 'dry, sticky mass' refusing to budge with...

Continue Reading
Amdocs Faces a Storm: Investor Alert as Legal Probe Begins

Updated Category News Views 64

Amdocs' Recent Crisis: What Investors Need to Know Lately, it seems Amdocs Limited (NASDAQ: DOX) has found itself knee-deep in a situation that could make seasoned investors cringe. November shone some harsh light on the company's operations, a move that’s attracted attention from Schall, Brown & Schwartz LLP (“SBS”), a name not exactly foreign to shareholder...

Continue Reading
Wall Street Gains Hold Amid Volatility Drop

Updated Category News Views 66

A Week of Gains and Regulatory Moves Right out of the gate, it’s been a decent stretch for Wall Street. Weekly gains kept the party going, even as traders navigated the usual hurdles. Stocks finished the week with a solid performance—all the heavy hitters like Dow, S&P 500, Nasdaq, and Russell 2000 ended on a high note, waltzing uphill past where many imagined...

Continue Reading
TYYY Liquidation Leaves Holders With a Tight Exit Window

Updated Category News Views 79

A fund can vanish faster than investors can read the fine print, and TYYY is doing exactly that. Exchange Traded Concepts has approved the closure and liquidation of the xETFs TSLA Daily Income ETF, with the fund expected to cease operations and distribute cash on or about November 20, 2026. This is not a debate about whether holders should love or hate Tesla. The product...

Continue Reading

Top 5 Most Recently Viewed Articles

Brooge Energy Shareholders Take Action Against Ernst & Young

Updated Category News Views 408

Investors Initiate Legal Action Against Ernst & Young In a significant development for Brooge Energy, some shareholders have lodged a fraud complaint against Ernst & Young in the United States. They accuse the auditor of failing to uncover significant discrepancies in the oil storage firm's financial reports over two years. The Allegations Explained The shareholders...

Continue Reading
Trakka Systems Shows Off ISR Tech at Farnborough Airshow

Updated Category News Views 28

Trakka Systems Steals the Spotlight at Farnborough Trakka Systems, that familiar name in the critical vision game, is about to make some noise at the Farnborough International Airshow 2026 in the UK. Yep, they're rolling out live shindigs of their top-tier tech, and if you're near Stand C322, you won't want to miss it. It's all happening July 20–24, and you bet they're...

Continue Reading
Market Trends: Fastenal's Earnings and Stock Movements Today

Updated Category News Views 167

Stock Market Overview The U.S. stock market faced slight declines today, with the Dow Jones index dipping by approximately 0.1%. Following the opening of the market, the Dow decreased by 0.09%, settling at 44,330.95. Similarly, the NASDAQ fell by 0.09% to reach 20,566.69, while the S&P 500 experienced a minor decline of 0.17%, now standing at 6,249.07. Market Sector...

Continue Reading
Market Fluctuations: Traders Target Opportunities in Crypto Stocks

Updated Category News Views 264

Bitcoin's Impact on Crypto Stocks The recent drop in Bitcoin below $80,000 significantly affected crypto-related stocks, leading to declines in major companies like Coinbase Global Inc (COIN), Robinhood Markets Inc (HOOD), MARA Holdings Inc (MARA), and Riot Platforms Inc (RIOT). This downturn raised questions among traders about potential buying opportunities as the...

Continue Reading
Class Action Alert: PepGen Inc. Faces Securities Law Issues

Updated Category News Views 148

PepGen Inc. and the Class Action Lawsuit PepGen Inc. is currently embroiled in a class action lawsuit, and shareholders who have invested in the company might want to take note of their rights. This situation arose from allegations that the firm violated securities laws, leading to detrimental impacts for its investors. Shareholders are encouraged to understand the...

Continue Reading